Cancer
ISA Pharmaceuticals highlights positive clinical data at ASCO
June 6, 2023Research and Development ASCO, Cancer, HPV, ISA Pharmaceuticals, Oncology
Clinical stage biotechnology company ISA Pharmaceuticals has announced positive phase 1 data at the American Society of Clinical Oncology (ASCO) …
AstraZeneca shares oncology data at ASCO 2023
May 25, 2023Medical Communications ASCO, AstraZeneca, Cancer, Oncology, oncology
AstraZeneca plans to share data from its oncology pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting on …
AstraZeneca announces positive results from phase 3 trial for Tagrisso plus chemotherapy
May 17, 2023Research and Development AstraZeneca, Cancer, Oncology, Tagrisso, chemotherapy
AstraZeneca has announced positive results from the FLAURA2 phase 3 trial which showed that Tagrisso (osimertinib), in combination with chemotherapy, …
Thermo Fisher and Pfizer collaborate on NGS-based cancer tests
May 10, 2023Medical Communications Cancer, NGS, Oncology, Pfizer, Thermo Fisher Scientifitic, oncology
Scientific equipment provider Thermo Fisher and US pharmaceutical firm Pfizer have announced a collaboration to advance next-generation sequencing (NGS)-based cancer …
‘It’s Time for Trodelvy’: Charity launches petition against Gilead for drug access
July 19, 2021Sales and Marketing Cancer, Gilead, NHS, charity
The charity Breast Cancer Now has launched a petition calling on Gilead to provide free-of-charge access to its new treatment …
Personalised medicine in oncology: Where are we now?
June 30, 2021Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, Cancer, oncology, presonalised medicine, surgery
The past decade has seen exponential growth in the field of oncology, with precision medicine at the forefront, driving positive …
Breakthrough announced in circulating tumour cell research
June 18, 2021Medical Communications Cancer, Circulating tumour cells, Precision Medicine, oncology
Liquid biopsy company, Angle, has announced results from their study in non-small cell lung cancer (NSCLC) which demonstrates the benefit …
New class of cancer-killing drugs identified
June 18, 2021Medical Communications Cancer, oncology
Scientists have announced the identification of a new class of cancer drugs, known as POLQ inhibitors, that specifically kill cancer …
BMS announce new positive data from oesophageal cancer study
June 4, 2021Medical Communications Cancer, oncology
Bristol Myers Squibb (BMS) has announced results from the Phase III CheckMate -648 trial in which nivolumab plus chemotherapy and …
Researchers find possible new treatment for several cancers
April 23, 2021Medical Communications Cancer, The Institute of Cancer Research, cancer treatment, kidney cancer treatment, pharma, pharma news
Researchers at The Institute of Cancer Research (ICR) in London have discovered a new use for an ovarian and breast …
Amgen stomach cancer drug awarded Breakthrough Therapy Designation
April 21, 2021Research and Development Amgen, Cancer, cancer treatment, pharma, pharma news
Amgen’s investigational therapy, bemarituzumab, for certain types of stomach and esophagus cancer, has been granted Breakthrough Therapy Designation by the …
BC Platforms partners with Australian Tissue Bank to improve breast cancer treatment
April 13, 2021Manufacturing and Production Cancer, data
BC Platforms have announced a data partnership with the Australian Breast Cancer Tissue Bank (ABCTB) for its BCRQUEST.com Global Data …
EC approves combination treatment for kidney cancer
March 31, 2021Research and Development Cancer, Europe, oncology
The European Commission (EC) has approved Ipsen’s Cabometyx in combination with Opdivo as a first-line treatment for advanced renal cell …
NHS agrees on MSD interim colorectal cancer treatment
March 25, 2021COVID-19, Cancer, MSD, NHS
MSD has announced a provisional agreement with the NHS to make KEYTRUDA (pembrolizumab) available for eligible patients with metastatic MSI-H/dMMR …
eTheRNA awarded €6.9 million TIGER Grant by European Commission
March 22, 2021Sales and Marketing Cancer, EU
eTheRNA immunotherapies, a clinical-stage company, has been awarded a grant of €6.9 million by the European Commission to develop a …
Latest content
